Summary of Significant Accounting Policies - Segment (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
segment
|
Jun. 30, 2024
USD ($)
|
|
| Accounting Policies [Abstract] | ||||
| Number of operating segments | segment | 1 | |||
| Research And Development Expense By Major Programs [Line Items] | ||||
| Research and development | $ 40,517 | $ 57,510 | $ 91,328 | $ 121,624 |
| Birtamimab (NEOD001) | ||||
| Research And Development Expense By Major Programs [Line Items] | ||||
| Research and development | 19,433 | 21,565 | 45,347 | 42,749 |
| PRX012 | ||||
| Research And Development Expense By Major Programs [Line Items] | ||||
| Research and development | 15,093 | 31,994 | 33,168 | 69,807 |
| PRX019 | ||||
| Research And Development Expense By Major Programs [Line Items] | ||||
| Research and development | 1,824 | 676 | 3,926 | 1,457 |
| Other Research And Development | ||||
| Research And Development Expense By Major Programs [Line Items] | ||||
| Research and development | $ 4,167 | $ 3,275 | $ 8,887 | $ 7,611 |